News & Videos - MATINAS BIOPHARMA HLDGS

Sydney, Australia (ABN Newswire) - In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr. Jabbour will address Matinas' First Quarter 2019 Financial Results with an outlook toward the next 12 months. To view the Video Audio, please visit: http://www.abnnewswire.net/press/en/98116/MTNB To view...

Sydney, Australia (ABN Newswire) - Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma, (NYSE:MTNB). Matinas BioPharma proprietary, disruptive technology utilizes a lipid nano-crystal (LNC) platform technology which can encapsulate small molecule drugs, ologonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. Today Mr. Jabbour discusses the development of...

Bedminster, NJ, United States (ABN Newswire) - Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma (NYSEAMERICAN:MTNB). Matinas BioPharma proprietary, disruptive technology utilizes a lipid nano-crystal (LNC) platform technology which can encapsulate small molecule drugs, ologonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. Mr. Jabbour discusses the...

-- Several data milestones anticipated during 1H 2017 -- Recent warrant tender offer resulting in $13.5 million in gross proceeds strengthens balance sheet and extends cash runway into 2Q 2018 -- New GLP/cGMP manufacturing facility positions Company for expected pivotal programs for MAT2203 and MAT2501 -- Up-list to a national securities exchange expected in 1Q 2017 BEDMINSTER, N.J., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage...

BEDMINSTER, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour , Co-founder and President will present at NobleCon13, the Noble Capital Markets’ Thirteenth Annual Investor Conference, on January 30, 2017 at 1:00 p.m. ET in Boca Raton, FL. During his presentation, Mr. Jabbour will provide a corporate and...

BEDMINSTER, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today the successful completion of its tender offer to amend and exercise certain categories of existing warrants, which expired at 5:00 p.m. Eastern Standard Time on January 13, 2017. The gross cash proceeds from the warrant exercises were $13.5 million with net cash...

BEDMINSTER, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour , Co-Founder and President, will present at the 9 th Annual Biotech Showcase conference on January 11, 2017 at 9:00 a.m. PT in San Francisco, CA. During his presentation, Mr. Jabbour will provide a corporate and clinical update, and will discuss...

– MAT2501 previously received Orphan Drug and Qualified Infectious Disease Product designations for treatment of nontuberculous mycobacterium infections by U.S. FDA – – Phase 1 data expected in the first half of 2017 – BEDMINSTER, N.J., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and...

- Second Phase 2 study of lead anti-infective candidate MAT2203 - – On track to report Phase 2 topline data for MAT2203 in the first half of 2017 – BEDMINSTER, N.J., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced today that it has initiated enrollment and the...

– Company to commence initial study in the Phase 1 program for MAT2501 and second Phase 2 study for MAT2203 in Q4 2016 – – On track to report Phase 2 topline data for MAT2203 in the first half of 2017 – BEDMINSTER, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections,...

BEDMINSTER, N.J., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced the presentation of positive preclinical data demonstrating its cochleate lipid-crystal nano-particle drug delivery technology significantly enhances the immune response of intranasally or orally...

BEDMINSTER, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced that it received Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for U.S. Patent Application Serial No.13/854,487 entitled, “Geodate Delivery Vehicles.” The...

BEDMINSTER, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced today that Jerome D. Jabbour , Co-Founder and President, will present at the 2 nd Annual Dawson James Securities Growth Stock Conference on October 20, 2016 at 12:15 p.m. ET. Mr. Jabbour will provide...